Additionally, another study reported the association of CYP3A4*18B with the incidence of tacrolimus-induced new-onset diabetes while reporting no association of CYP3A5 variants with new-onset type 2 diabetes in renal transplant recipients [32], but these studies were on study participants with different disease conditions and types of treatment than our study participants that limited direct comparison. This evidence concerns the gene CYP3A4 and type 2 diabetes mellitus.